Leukemia: A Review of Data from the ASH 2022 Meeting

Elias Jabbour, MD, an expert on leukemia

EP. 1: ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape

BySameem Abedin, MD,Elias Jabbour, MD,Harry Erba, MD, PhD,Anjali Advani, MD

February 14th 2023

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Anjali Advani, MD, an expert on leukemia

EP. 2: ASH 2022: Recent Advances in Chronic Myeloid Leukemia

BySameem Abedin, MD,Elias Jabbour, MD,Harry Erba, MD, PhD,Anjali Advani, MD

February 14th 2023

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Harry Erba, MD, PhD, an expert on leukemia

EP. 3: Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting

BySameem Abedin, MD,Elias Jabbour, MD,Harry Erba, MD, PhD,Anjali Advani, MD

February 14th 2023

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

Trending on OncLive

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

The OncFive: Top Oncology Articles for the Week of 9/27/2026

AUA Releases Guideline Amendment for NMIBC

Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer

FLORA-2 Updates at World Lung: Biomarker Analysis, Safety Follow-Up, and ctDNA Monitoring